Nkarta

NKTX · NASDAQ

$1.74−$0.01 (−0.57%)TodayMarket closed · Oct 20, 7:41 PM ET

Prev close $1.75

NKTX analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $11.05 (+535.1% upside)

Low: $9.09
Now: $1.74
High: $14.70

Upgrades and downgrades

The latest rating actions, newest first

NKTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Stifel	Aug 14, 2026	Maintains	Buy	$11.00 → $10.00	46%
HC Wainwright & Co.	Aug 11, 2026	Maintains	Buy	$16.00 → $14.00	27%
Needham	May 13, 2026	Maintains	Buy	$11.00	38%
Mizuho	Mar 31, 2026	Maintains	Outperform	$14.00 → $12.00	40%
Needham	Mar 26, 2026	Maintains	Buy	$10.00 → $11.00	38%
Stifel	Nov 11, 2025	Maintains	Buy	$12.00 → $11.00	46%

The case for and against

Updated Oct 15, 2026

Bull case

Nkarta is viewed favorably because the April 2026 trial amendments meaningfully improve enrollment economics by reducing monitoring burden, enabling outpatient dosing, broadening access to community rheumatology centers, and allowing re-dosing, all of which should accelerate Ntrust-1/2 execution. The company also has a differentiated allogeneic CAR-NK platform with scalable sourcing, engineering, and manufacturing advantages, while early competitive and precedent data in lupus nephritis, SLE, and systemic sclerosis support proof-of-concept for NKX019 and its potential as a quicker-to-market asset. With initial Ntrust-1/2 data expected at an as-yet-unspecified 2026 medical meeting and emphasis on 6+ patients at the highest 4B cells/dose with 3+ months of follow-up, the setup appears to de-risk the broader story and supports the Buy view.

Bear case

Nkarta is viewed cautiously because 2Q26 operating expenses rose 40% sequentially to $43.1M and exceeded estimates, while EPS of ($0.54) underscores continued losses and weak operating leverage. Although the company ended 2Q26 with $243.2M in cash and equivalents, spending is still expected to total $148.3M in 2026 and the runway depends on continued clinical execution without clear commercial offset. Its outlook remains pressured by early-stage programs in Phase I or preclinical development, no FDA or EMA-approved NK cell therapies to validate the space, and intense competition from other cellular therapy developers.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.